Assessment of Drug Liking In Peri-procedural Clinical Settings
Launched by STANFORD UNIVERSITY · Jun 3, 2025
Trial Information
Current as of August 31, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to explore how certain medications given during medical procedures might affect people's feelings about those drugs, specifically focusing on a medication called fentanyl, which is commonly used for pain relief. The goal is to understand whether the way these medications are administered can change how much patients "like" or prefer them.
To be eligible for this study, participants need to be between the ages of 65 and 74 and have a specific health classification that indicates they are in fairly good overall health. They should be scheduled to receive fentanyl as part of their treatment for a procedure, like an endoscopy. However, individuals with certain health conditions, such as severe breathing issues or a history of mental health disorders, cannot participate. If you join the study, you'll help researchers learn more about how medications affect patients’ experiences, which could lead to better pain management strategies in the future. Please note that the trial is not yet recruiting participants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) physical status classification of I, II or III
- • Candidates who are expected to receive fentanyl up to 3 mcg/kg IBW for their scheduled for surgery or procedure (for example, endoscopies)
- • Exclusion Criteria.
- • Craniofacial abnormalities
- • Known or suspected difficult intubation or mask ventilation
- • Known or suspected need for rapid sequence induction and intubation
- • Allergies or hypersensitivities to droperidol or fentanyl
- • Clinically significant pulmonary disease, such as chronic obstructive lung disease requiring long-term oxygen therapy, or other conditions that, in the study team's judgment, may increase the risk of severe respiratory depression with opioid administration
- • History of long QT syndrome
- • History of Torsades de Pointes
- • History of psychosis
- • History of movement disorders e.g. Parkinson's Disease
- • Past chronic use of anti-psychotics
- • Current use of droperidol, levodopa, lithium, clozapine, metoclopramide, benzodiazepines
- • Current use of opioids
- • History of opiate abuse within the last 3 years
- • Known or suspected severe chronic pain condition that require use of opiates or limit daily activities
- • History of pheochromocytoma
- • History of concomitant prolactin-dependent tumors e.g. prolactinoma, breast cancer
- • Pregnancy or nursing
- • Failure to satisfy the investigator of fitness to participate for any other reason
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Patrick L Purdon, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported